# Standard BioTools (LAB) — Earnings

LAB · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/lab/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.07 |
| EPS estimate | −$0.01 |
| EPS surprise | −446.88% |
| Revenue surprise | −3.37% |
| Revenue | $20.1M |
| Revenue estimate | $20.8M |
| Reported | Aug 5, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1162194/000119312526335103/lab-20260630.htm) |

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 5, 2026 | −$0.01 | −$0.07 | -446.88% | $20.8M | $20.1M |
| Q1 2026 | May 5, 2026 | −$0.05 | −$0.04 | 14.35% | $17.8M | $21.1M |
| Q4 2025 | Feb 24, 2026 | −$0.05 | $0.04 | 174.21% | $18.5M | $23.8M |
| Q3 2025 | Nov 4, 2025 | −$0.04 | −$0.09 | -107.85% | $18.0M | $19.6M |
| Q2 2025 | Aug 11, 2025 | −$0.07 | −$0.05 | 25.04% | $39.8M | $21.8M |
| Q1 2025 | May 6, 2025 | −$0.06 | −$0.07 | -27.27% | $40.1M | $40.8M |
| Q4 2024 | Feb 26, 2025 | −$0.06 | −$0.09 | -58.73% | $43.0M | $46.7M |
| Q3 2024 | Oct 30, 2024 | −$0.09 | −$0.07 | 22.22% | $41.0M | $45.0M |
| Q2 2024 | Jul 31, 2024 | −$0.08 | −$0.12 | -44.06% | $48.2M | $37.2M |
| Q1 2024 | May 8, 2024 | −$0.11 | −$0.27 | -140.21% | $46.0M | $45.5M |
| Q4 2023 | Feb 28, 2024 | −$0.24 | −$0.25 | -4.17% | $24.9M | $28.2M |
| Q3 2023 | Nov 7, 2023 | −$0.23 | −$0.27 | -17.39% | $23.6M | $25.4M |
| Q2 2023 | Aug 8, 2023 | −$0.21 | −$0.22 | -4.76% | $24.2M | $27.7M |
| Q1 2023 | May 9, 2023 | −$0.06 | −$0.21 | -279.75% | $28.4M | $25.1M |
| Q4 2022 | Feb 14, 2023 | −$0.11 | −$0.26 | -136.36% | $38.0M | $27.0M |
| Q3 2022 | Nov 8, 2022 | −$0.13 | −$0.37 | -184.62% | $30.9M | $25.6M |
| Q2 2022 | Aug 8, 2022 | −$0.13 | −$0.82 | -530.77% | $29.8M | $18.8M |
| Q1 2022 | May 5, 2022 | −$0.15 | −$0.99 | -560.00% | $25.6M | $26.5M |
| Q4 2021 | Feb 18, 2022 | −$0.28 | −$0.12 | 57.14% | $32.7M | $38.3M |
| Q3 2021 | Nov 8, 2021 | −$0.22 | −$0.18 | 18.18% | $30.0M | $28.5M |

## Frequently Asked Questions

### When did Standard BioTools (LAB) last report earnings?

Standard BioTools last reported on Aug 5, 2026, covering fiscal Q2 2026.

### Did LAB beat earnings estimates?

No. Standard BioTools reported EPS of −$0.07 for Q2 2026 against a −$0.01 estimate — a 446.88% miss.

### How much revenue did LAB report last quarter?

Standard BioTools reported $20.1M in revenue for Q2 2026, against a consensus estimate of $20.8M.

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).